<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/060C89E9-66C5-4F7B-B010-218C2A4B88D5"><gtr:id>060C89E9-66C5-4F7B-B010-218C2A4B88D5</gtr:id><gtr:name>Okairos</gtr:name><gtr:address><gtr:line1>Viale Citt? d'Europa, 679</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Clinical Medicine</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/060C89E9-66C5-4F7B-B010-218C2A4B88D5"><gtr:id>060C89E9-66C5-4F7B-B010-218C2A4B88D5</gtr:id><gtr:name>Okairos</gtr:name><gtr:address><gtr:line1>Viale Citt? d'Europa, 679</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/17719B3D-8D27-40E3-967A-65E55AE07A99"><gtr:id>17719B3D-8D27-40E3-967A-65E55AE07A99</gtr:id><gtr:firstName>Adrian</gtr:firstName><gtr:surname>Hill</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0502018"><gtr:id>7360CCBC-D26A-4039-B437-DB7EB851858F</gtr:id><gtr:title>Malaria Adenoviral Vaccine</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0502018</gtr:grantReference><gtr:abstractText>Malaria is one of the greatest causes of infectious mortality globally but no vaccine is available. For over ten years it has been known that a particular type of immune response can impart strong protection against malaria. This entails a cellular immune response by killer T cells against the malaria parasite growing in liver cells. A new type of attenuated safe virus that can carry malaria genes has been developed as a vaccine that can induce these killer cells very strongly and protect against rodent malaria. We shall generate a vaccine of this type and test its ability to protect vaccinated individuals against malaria infection. If successful this approach could help develop vaccines of a similar type against a variety of other diseases.</gtr:abstractText><gtr:technicalSummary>A highly effective vaccine against malaria could have a substantial impact on the global disease burden. One of the best defined immune protective mechanisms against malaria is the ability of CD8 T cells that target pre-erythrocytic antigens to clear the liver of infected cells. However, induction of strong enough CD8 T cell responses by vaccination in humans to produce useful levels of protection has been difficult. 
 Extensive comparisons of vaccine delivery systems in animals and more limited human data point to adenoviral vectors as probably the most potent means of inducing a CD8 T cell response against pathogen antigens. However, the utility of common adenovirus vectors in humans is greatly impaired by high prevalences of antibodies to common human adenovirus serotypes, especially in developing world populations.
 We have assessed newly available simian adenovirus vectors of chimpanzee origin and find that their immunogenicity is not impaired by immunity to common human adenoviruses. The immunogenicity of a specific simian vector, AdC68, is greater than the commonly used human serotype 5 vector and generates high level single dose protection in a murine malaria model.
 We propose to assess the safety, immunogenicity and efficacy of this novel candidate vaccine encoding the protective P. falciparum insert ME.TRAP in a phase I / IIa sporozoite challenge study. The first aim is to show that this replication-deficient simian adenovirus vector appears safe in healthy human volunteers. The second is to generate the highest recorded level of CD8 T cell immunogenicity and show that this is not impaired by pre-existing immunity to human adenoviruses. This result would impact on vaccination against many diseases other than malaria. The final aim is to demonstrate an unprecedented level of protection against sporozoite challenge in humans, which would lead to rapid further development of this approach to an effective malaria vaccine.</gtr:technicalSummary><gtr:fund><gtr:end>2009-01-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2006-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>647586</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Okairos</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>Okairos collaboration</gtr:description><gtr:id>55A484A4-AD9C-42C6-9138-CEC9233BDE2F</gtr:id><gtr:impact>The phase I / IIa clinical trial has been exceptionally successful, providing to our knowledge the first example of CD8 T cell mediated protection by vaccination against a disease.</gtr:impact><gtr:outcomeId>2BC6589A873-1</gtr:outcomeId><gtr:piContribution>We undertook a clinical trial with a vaccibe vector that was provided by Okairos</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1600000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>European and Developing Countries Clinical Trials Partnership</gtr:department><gtr:description>EDCTP Malaria vaccine trials</gtr:description><gtr:end>2013-12-02</gtr:end><gtr:fundingOrg>Sixth Framework Programme (FP6)</gtr:fundingOrg><gtr:id>A2170DEA-5AA6-4E82-933A-26EB4DA00FB4</gtr:id><gtr:outcomeId>A80F34219360</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2009-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>700000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EMVI vaccine development</gtr:description><gtr:end>2012-08-02</gtr:end><gtr:fundingOrg>European Vaccine Initiative (EVI)</gtr:fundingOrg><gtr:id>2365630E-E22B-49C5-BCED-3991EDC0D29E</gtr:id><gtr:outcomeId>805888149120</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1000000</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>PATH Malaria Vaccine Initiative</gtr:department><gtr:description>Funding from the PATH Malaria Vaccine Initiative</gtr:description><gtr:end>2014-06-02</gtr:end><gtr:fundingOrg>PATH</gtr:fundingOrg><gtr:id>55605940-1066-438C-B6FA-C5A804043F38</gtr:id><gtr:outcomeId>D22FxQ1qKGk</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-02-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>efficacy result</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>66D664F1-3EB5-4036-BE21-47D8D6406B91</gtr:id><gtr:outcomeId>2B633369445</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>A prime-boost malaria vaccine encoding the MeTRAP pre-erythrocytic insert expressed by the AdCh63 adenoviral vector and an MVA vector</gtr:description><gtr:id>4A097E37-57BF-4AF0-B0B4-04589FC55028</gtr:id><gtr:impact>In a phase IIa sporozoite challenge trial this vaccination approach induced high levels of CD8 T cells that correlated with vaccine efficacy.</gtr:impact><gtr:outcomeId>FFDED01B90E</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>ChAd-MVA vaccination regime</gtr:title><gtr:type>Therapeutic Intervention - Vaccines</gtr:type><gtr:yearDevCompleted>2009</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>reagents for and method of malaria vaccination</gtr:description><gtr:id>A12B3C89-5AA7-40A5-BD31-77EEFC2444B6</gtr:id><gtr:impact>In a first phase IIa sporozoite challenge study these vaccine showed significant efficacy</gtr:impact><gtr:outcomeId>DAC089D00F6</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>improved malaria vaccination regime</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:url>http://www.jenner.ac.uk</gtr:url></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>Vaccitech</gtr:companyName><gtr:description>This Oxford spin-out company is developing simian adenoviral vectors as vaccines to prevent and treat diseases: specifically influenza and prostate cancer. Both candidate vaccines are in phase II trials.</gtr:description><gtr:id>1A24EC50-0A43-43EF-BDD4-8375E1445D5E</gtr:id><gtr:impact>Attracted &amp;pound;10M as an initial investment from Oxford Sciences Innovations</gtr:impact><gtr:outcomeId>58c7bf2149f6e6.22402985</gtr:outcomeId><gtr:url>http://www.vaccitech.co.uk</gtr:url><gtr:yearCompanyFormed>2016</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication><gtr:id>3108A65C-59A1-47F2-84DD-77CA64DE7BF5</gtr:id><gtr:title>Distinguishing malaria and influenza: early clinical features in controlled human experimental infection studies.</gtr:title><gtr:parentPublicationTitle>Travel medicine and infectious disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6c7171b7961f3deba4f707f92470fada"><gtr:id>6c7171b7961f3deba4f707f92470fada</gtr:id><gtr:otherNames>Lillie PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1477-8939</gtr:issn><gtr:outcomeId>pm_16119_29_22531678</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>81B0FAA1-2AB3-4FE7-BC17-1784464EFC3D</gtr:id><gtr:title>Comparison of modeling methods to determine liver-to-blood inocula and parasite multiplication rates during controlled human malaria infection.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c14f468562fffaa13dd59e4fc7fddc23"><gtr:id>c14f468562fffaa13dd59e4fc7fddc23</gtr:id><gtr:otherNames>Douglas AD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>pm_16119_29_23570846</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>75DF36D7-ACEE-4B6B-AF99-49875F35C0E4</gtr:id><gtr:title>Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7e9f161d0d5724a4e59753ed3f3be8de"><gtr:id>7e9f161d0d5724a4e59753ed3f3be8de</gtr:id><gtr:otherNames>Ogwang C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_16119_29_23526949</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0EEDB047-EBC5-4077-B835-B7A58C6DFAFA</gtr:id><gtr:title>Prevalence of serum neutralizing antibodies against chimpanzee adenovirus 63 and human adenovirus 5 in Kenyan children, in the context of vaccine vector efficacy.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0b4942f4f386e35323e514920dc52426"><gtr:id>0b4942f4f386e35323e514920dc52426</gtr:id><gtr:otherNames>Dudareva M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>5820148AAF4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>24EDBDA7-33DB-4FE1-8F5E-3A774D406319</gtr:id><gtr:title>Translating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populations.</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e3c35bf1abd5410636007a1fc06dcfea"><gtr:id>e3c35bf1abd5410636007a1fc06dcfea</gtr:id><gtr:otherNames>Kimani D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn><gtr:outcomeId>5a325d8275b6d6.02912924</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>87AF57C7-7E6D-4A01-B74B-C962A11DA407</gtr:id><gtr:title>Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and Infants.</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5bd0b08c7569d3fbb892d3070c540098"><gtr:id>5bd0b08c7569d3fbb892d3070c540098</gtr:id><gtr:otherNames>Afolabi MO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn><gtr:outcomeId>58c7c1e6149102.88185976</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D53BAD88-5868-4D82-B285-032E307E8515</gtr:id><gtr:title>Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2da65024ea62296e117b26b34c3dc53a"><gtr:id>2da65024ea62296e117b26b34c3dc53a</gtr:id><gtr:otherNames>O'Hara GA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>Y3HPsZoVtuH</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D1D00252-AEAF-4BD1-990E-AE6B372C7643</gtr:id><gtr:title>Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses.</gtr:title><gtr:parentPublicationTitle>Infection and immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/730d82392726a3f1a01f32412d7e15a3"><gtr:id>730d82392726a3f1a01f32412d7e15a3</gtr:id><gtr:otherNames>Reyes-Sandoval A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0019-9567</gtr:issn><gtr:outcomeId>499722D67B3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D094B83D-FE3A-4A03-9B86-8877DBF822F2</gtr:id><gtr:title>Determining the validity of hospital laboratory reference intervals for healthy young adults participating in early clinical trials of candidate vaccines.</gtr:title><gtr:parentPublicationTitle>Human vaccines &amp; immunotherapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/03bf3021d170ffb53155b63a4e9d5cf8"><gtr:id>03bf3021d170ffb53155b63a4e9d5cf8</gtr:id><gtr:otherNames>Rowland R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2164-5515</gtr:issn><gtr:outcomeId>pm_16119_29_23733037</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B9D3367D-778E-48E2-93DB-9F0B5E51D668</gtr:id><gtr:title>Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species.</gtr:title><gtr:parentPublicationTitle>Science translational medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1e878b1af1aa4bdbd1966248e20dba0a"><gtr:id>1e878b1af1aa4bdbd1966248e20dba0a</gtr:id><gtr:otherNames>Colloca S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1946-6234</gtr:issn><gtr:outcomeId>pm_16119_29_22218691</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B17E86A6-6A3D-433E-8125-8F9782ABDD68</gtr:id><gtr:title>Vaccines against malaria.</gtr:title><gtr:parentPublicationTitle>Philosophical transactions of the Royal Society of London. Series B, Biological sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7d3a980f9c391b7f04b390cf1765ebdd"><gtr:id>7d3a980f9c391b7f04b390cf1765ebdd</gtr:id><gtr:otherNames>Hill AV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0962-8436</gtr:issn><gtr:outcomeId>QBDDCbXTBiB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>826D74DF-049E-4C1C-9F76-27C8869A6A70</gtr:id><gtr:title>Comparison of clinical and parasitological data from controlled human malaria infection trials.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/058c1ccbe665a5aaa6371b395f1d2b02"><gtr:id>058c1ccbe665a5aaa6371b395f1d2b02</gtr:id><gtr:otherNames>Roestenberg M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_16119_29_22701640</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0502018</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>D8F3A27D-084A-40BB-A046-087DACE23410</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>3.4  Vaccines</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>